Chemistry:Bifeprunox

Short description: Experimental dopamine D2 receptor partial agonist researched as an antipsychotic agent

Bifeprunox

Clinical data
ATC code	none
Identifiers
IUPAC name 7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]-1,3-benzoxazol-2(3H)-one
CAS Number	350992-10-8 N
PubChem CID	208951
ChemSpider	181044 Y
UNII	AP69E83Z79
ChEMBL	ChEMBL218166 Y
Chemical and physical data
Formula	C24H23N3O2
Molar mass	385.467 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C2Oc1c(cccc1N2)N5CCN(Cc4cccc(c3ccccc3)c4)CC5
InChI InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28) Y Key:CYGODHVAJQTCBG-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D₂ receptor agonism with serotonin receptor agonism. It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.

In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007. In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."

Pharmacodynamics

Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.

See also

• Aripiprazole
• Pardoprunox